Key Points
-
MHC class I molecules present peptide fragments mostly from nuclear and cytosolic antigens. Although the process is reasonably well characterized, the origin and whereabouts of the peptides has only recently become clear.
-
The latest additions to the scheme are peptidases. Various cytosolic aminopeptidases and an endoplasmic reticulum (ER) aminopeptidase have been defined. The half-life of peptides (∼5 seconds) in living cells has been determined.
-
Peptides can be derived not only from old proteins, but also from the same proteins that are degraded almost immediately after generation. This can be the result of defects in translation, folding or assembly, and the products are collectively known as defective ribosomal products (DRiPs). DRiPs are important to allow a rapid CD8+ T-cell response after infection.
-
Contrary to intuition, the process of antigen processing and presentation is inefficient. Potential antigens are destroyed at various levels including the proteasome, cytosolic peptidases and ER peptidases. The result of these processes is that only about one peptide out of every 10,000 proteins degraded will be presented by MHC class I molecules.
-
Many estimates have been made for the activities of the different steps in MHC class-I-antigen presentation. These numbers explain the inefficiency of MHC class-I-antigen presentation.
-
The inefficiency of antigen presentation sets a threshold on the minimum number of protein copies expressed for recognition by CD8+ T cells.
Abstract
MHC class I molecules bind short peptides and present them to CD8+ T cells. Contrary to textbook descriptions, the generation of MHC class-I-associated peptides from endogenous proteins is a highly dynamic and remarkably inefficient process. Here, we describe recent experiments that show how nascent and mature proteins are degraded into peptides that are trimmed, transported and trimmed again to enable presentation of a small portion of the generated peptides. By linking the failure rate of protein synthesis with antigen presentation, a rapid T-cell response is ensured, which is crucial in combating viral infections. Presentation on MHC class I molecules is achieved by less than 0.1% of the specific peptides that have survived intracellular destruction. The other peptides are converted into free amino acids that are used for recycling into new proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Garboczi, D. N. et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384, 134–141 (1996).
Garcia, K. C. et al. An αβ T cell receptor structure at 2. 5 Å and its orientation in the TCR–MHC complex. Science 274, 209–219 (1996).
Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H. G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290–296 (1991).
Rock, K. L. et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761–771 (1994).
Reits, E. A., Benham, A. M., Plougastel, B., Neefjes, J. & Trowsdale, J. Dynamics of proteasome distribution in living cells. EMBO J. 16, 6087–6094 (1997).
Kisselev, A. F., Akopian, T. N., Woo, K. M. & Goldberg, A. L. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274, 3363–3371 (1999). This paper identifies the peptides that are generated by the proteasome under in vitro conditions. Only a small fraction of all peptides that are released by the proteasomes can bind directly with high affinity to MHC class I molecules. A marked fraction of peptides are too short for transport by transporter for antigen processing (TAP) and binding to MHC class I molecules.
Reits, E. et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18, 97–108 (2003). This report describes the fate of peptides in living cells. Using bleaching techniques, it is shown that peptides associate with chromatin. However, peptides have to leave the nucleus to contact TAP and are rapidly degraded in the cytoplasm by resident peptidases. As a result, more than 99% will not reach TAP for translocation into the endoplasmic reticulum (ER).
Serwold, T., Gonzalez, F., Kim, J., Jacob, R. & Shastri, N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419, 480–483 (2002).
Saric, T. et al. An IFN-γ-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nature Immunol. 3, 1169–1176 (2002).
Neefjes, J. J., Momburg, F. & Hammerling, G. J. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261, 769–771 (1993).
van Endert, P. M., Saveanu, L., Hewitt, E. W. & Lehner, P. Powering the peptide pump: TAP crosstalk with energetic nucleotides. Trends Biochem. Sci. 27, 454–461 (2002).
Ortmann, B. et al. A critical role for tapasin in the assembly and function of multimeric MHC class I–TAP complexes. Science 277, 1306–1309 (1997).
Garbi, N. et al. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nature Immunol. 1, 234–238 (2000).
Dick, T. P., Bangia, N., Peaper, D. R. & Cresswell, P. Disulfide bond isomerization and the assembly of MHC class I–peptide complexes. Immunity 16, 87–98 (2002).
Cascio, P., Hilton, C., Kisselev, A. F., Rock, K. L. & Goldberg, A. L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20, 2357–2366 (2001).
Momburg, F., Roelse, J., Hammerling, G. J. & Neefjes, J. J. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J. Exp. Med. 179, 1613–1623 (1994).
Neisig, A., Wubbolts, R., Zang, X., Melief, C. & Neefjes, J. Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J. Immunol. 156, 3196–3206 (1996).
Zweerink, H. J. et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 150, 1763–1771 (1993).
Wei, M. L. & Cresswell, P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356, 443–446 (1992).
Williams, D. B., Swiedler, S. J. & Hart, G. W. Intracellular transport of membrane glycoproteins: two closely related histocompatibility antigens differ in their rates of transit to the cell surface. J. Cell Biol. 101, 725–734 (1985).
Neefjes, J. J. & Ploegh, H. L. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with β2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur. J. Immunol. 18, 801–810 (1988).
Lammert, E., Stevanovic, S., Brunner, J., Rammensee, H. G. & Schild, H. Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum. Eur. J. Immunol. 27, 1685–1690 (1997).
Spee, P. & Neefjes, J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 27, 2441–2449 (1997).
Koopmann, J. O. et al. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity 13, 117–127 (2000).
Roelse, J., Gromme, M., Momburg, F., Hammerling, G. & Neefjes, J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J. Exp. Med. 180, 1591–1597 (1994).
Seifert, U. et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nature Immunol. 4, 375–379 (2003).
Glas, R., Bogyo, M., McMaster, J. S., Gaczynska, M. & Ploegh, H. L. A proteolytic system that compensates for loss of proteasome function. Nature 392, 618–622 (1998).
Princiotta, M. F. et al. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc. Natl Acad. Sci. USA 98, 513–518 (2001).
Gromme, M. et al. Recycling MHC class I molecules and endosomal peptide loading. Proc. Natl Acad. Sci. USA 96, 10326–10331 (1999).
Kleijmeer, M. J. et al. Antigen loading of MHC class I molecules in the endocytic tract. Traffic 2, 124–137 (2001).
Jackson, P. K. et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol. 10, 429–439 (2000).
Glickman, M. H. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373–428 (2002).
Navon, A. & Goldberg, A. L. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol. Cell 8, 1339–1349 (2001).
Benaroudj, N., Zwickl, P., Seemuller, E., Baumeister, W. & Goldberg, A. L. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol. Cell 11, 69–78 (2003).
Ogura, T. & Tanaka, K. Dissecting various ATP-dependent steps involved in proteasomal degradation. Mol. Cell 11, 3–5 (2003).
Kloetzel, P. M. Antigen processing by the proteasome. Nature Rev. Mol. Cell Biol. 2, 179–187 (2001).
York, I. A. et al. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18, 429–440 (2003). This paper, together with reference 39, provides examples of various peptidases that either generate or destroy peptides for MHC class I antigen presentation. This depends on peptide size and sequence.
Stoltze, L. et al. Two new proteases in the MHC class I processing pathway. Nature Immunol. 1, 413–418 (2000).
York, I. A. et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8–9 residues. Nature Immunol. 3, 1177–1184 (2002).
Neisig, A. et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J. Immunol. 154, 1273–1279 (1995).
De Plaen, E. et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc. Natl Acad. Sci. USA 85, 2274–2278 (1988).
Schwab, S. R., Li, K. C., Kang, C. & Shastri, N. Constitutive display of cryptic translation products by MHC class I molecules. Science 301, 1367–1371 (2003).
Yewdell, J. W., Anton, L. C. & Bennink, J. R. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157, 1823–1826 (1996). The first paper to describe the concept of defective ribosomal products (DRiPs).
Bach, I. & Ostendorff, H. P. Orchestrating nuclear functions: ubiquitin sets the rhythm. Trends Biochem. Sci. 28, 189–195 (2003).
Jackson, P. K. & Eldridge, A. G. The SCF ubiquitin ligase: an extended look. Mol. Cell 9, 923–925 (2002).
Schimke, R. T. & Doyle, D. Control of enzyme levels in animal tissues. Annu. Rev. Biochem. 39, 929–976 (1970).
Goldberg, A. Intracellular protein degradation in mammalian and bacterial cells. Annu. Rev. Biochem. 45, 747–803 (1976).
Yewdell, J. W. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol. 11, 294–297 (2001).
Yewdell, J. W., Schubert, U. & Bennink, J. R. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J. Cell Sci. 114, 845–851 (2001).
Esquivel, F., Yewdell, J. & Bennink, J. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 175, 163–168 (1992).
Khan, S. et al. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 167, 4801–4804 (2001). References 51, 52 and 56 provide biochemical, cell biological and immunological evidence for the DRiP hypothesis. They imply that protein generation is tightly linked to antigen presentation by MHC class I molecules.
Reits, E. A., Vos, J. C., Gromme, M. & Neefjes, J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404, 774–778 (2000).
Schild, H. & Rammensee, H. G. Perfect use of imperfection. Nature 404, 709–710 (2000).
Wheatley, D. N. & Inglis, M. S. Turnover of nascent proteins in HeLa-S3 cells and the quasi-linear incorporation kinetics of amino acids. Cell Biol. Int. Rep. 9, 463–470 (1985).
Wheatley, D. N. Protein turnover in relation to growth status and the cell cycle in cultured mammalian cells. Revis. Biol. Cellular 21, 377–400 (1989).
Schubert, U. et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770–774 (2000).
Turner, G. C. & Varshavsky, A. Detecting and measuring cotranslational protein degradation in vivo. Science 289, 2117–2120 (2000).
Jensen, T. J. et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83, 129–135 (1995).
Ward, C. L., Omura, S. & Kopito, R. R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121–127 (1995).
Pareek, S. et al. Neurons promote the translocation of peripheral myelin protein 22 into myelin. J. Neurosci. 17, 7754–7762 (1997).
Notterpek, L., Ryan, M. C., Tobler, A. R. & Shooter, E. M. PMP22 accumulation in aggresomes: implications for CMT1A pathology. Neurobiol. Dis. 6, 450–460 (1999).
Siffroi-Fernandez, S., Giraud, A., Lanet, J. & Franc, J. L. Association of the thyrotropin receptor with calnexin, calreticulin and BiP. Efects on the maturation of the receptor. Eur. J. Biochem. 269, 4930–4937 (2002).
Petaja-Repo, U. E. et al. Newly synthesized human δ-opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. J. Biol. Chem. 276, 4416–4423 (2001).
Yedidia, Y., Horonchik, L., Tzaban, S., Yanai, A. & Taraboulos, A. Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J. 20, 5383–5391 (2001).
Drisaldi, B. et al. Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J. Biol. Chem. 278, 21732–21743 (2003).
Princiotta, M. F. et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18, 343–354 (2003). This paper shows the full quantification of the steps between protein synthesis and MHC class I antigen presentation. It visualizes the impact of DRiPs on MHC class-I-associated peptides.
Kenniston, J. A., Baker, T. A., Fernandez, J. M. & Sauer, R. T. Linkage between ATP consumption and mechanical unfolding during the protein processing reactions of an AAA+ degradation machine. Cell 114, 511–520 (2003).
Verma, R. & Deshaies, R. J. A proteasome howdunit: the case of the missing signal. Cell 101, 341–344 (2000).
Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M. & Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nature Biotechnol. 18, 538–543 (2000).
Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552–1555 (2001).
Falk, K., Rotzschke, O. & Rammensee, H. G. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348, 248–251 (1990).
Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. & Germain, R. N. Localization, quantitation, and in situ detection of specific peptide–MHC class I complexes using a monoclonal antibody. Immunity 6, 715–726 (1997).
Benham, A. M. & Neefjes, J. J. Proteasome activity limits the assembly of MHC class I molecules after IFN-γ stimulation. J. Immunol. 159, 5896–5904 (1997).
Anton, L. C. et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol. 160, 4859–4868 (1998).
Ben-Shahar, S. et al. 26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J. Biol. Chem. 274, 21963–21972 (1999).
Fruci, D. et al. Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J. Immunol. 170, 2977–2984 (2003).
Villanueva, M. S., Fischer, P., Feen, K. & Pamer, E. G. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1, 479–489 (1994).
Guermonprez, P. et al. ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425, 397–402 (2003).
Houde, M. et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 425, 402–406 (2003).
Denkberg, G. et al. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc. Natl Acad. Sci. USA 99, 9421–9426 (2002).
Jardetzky, T. S., Lane, W. S., Robinson, R. A., Madden, D. R. & Wiley, D. C. Identification of self peptides bound to purified HLA-B27. Nature 353, 326–329 (1991).
Admon, A., Barnea, E. & Ziv, T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol. Cell. Proteomics 2, 388–398 (2003).
Turzynski, A. & Mentlein, R. Prolyl aminopeptidase from rat brain and kidney. Action on peptides and identification as leucyl aminopeptidase. Eur. J. Biochem. 190, 509–515 (1990).
Beninga, J., Rock, K. L. & Goldberg, A. L. Interferon-γ can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273, 18734–18742 (1998).
Geier, E. et al. A giant protease with potential to substitute for some functions of the proteasome. Science 283, 978–981 (1999).
Macpherson, E., Tomkinson, B., Balow, R. M., Hoglund, S. & Zetterqvist, O. Supramolecular structure of tripeptidyl peptidase II from human erythrocytes as studied by electron microscopy, and its correlation to enzyme activity. Biochem. J. 248, 259–263 (1987).
Tomkinson, B. Tripeptidyl peptidases: enzymes that count. Trends Biochem. Sci. 24, 355–359 (1999).
Saric, T. et al. Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J. Biol. Chem. 276, 36474–36481 (2001).
Bromme, D., Rossi, A. B., Smeekens, S. P., Anderson, D. C. & Payan, D. G. Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry 35, 6706–6714 (1996).
Johnson, G. D. & Hersh, L. B. Studies on the subsite specificity of the rat brain puromycin-sensitive aminopeptidase. Arch. Biochem. Biophys. 276, 305–309 (1990).
Gakamsky, D. M., Davis, D. M., Strominger, J. L. & Pecht, I. Assembly and dissociation of human leukocyte antigen (HLA)-A2 studied by real-time fluorescence resonance energy transfer. Biochemistry 39, 11163–11169 (2000).
Thulasiraman, V., Yang, C. F. & Frydman, J. In vivo newly translated polypeptides are sequestered in a protected folding environment. EMBO J. 18, 85–95 (1999).
Acknowledgements
We thank C. Sanders at Vanderbilt University for providing examples of inefficient protein biogenesis. This work was supported by the Dutch Cancer Society KWF.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
41577_2003_BFnri1250_MOESM1_ESM.jpg
Cartoon 1 | MHC class I antigen presentation: the basics. Intracellular proteins are degraded by the proteasome into peptides. The transporter for antigen processing (TAP) then translocates peptides into the lumen of the endoplasmic reticulum (ER). Newly synthesized MHC class I molecules require peptide binding for release from the ER and transport to the plasma membrane, where the peptide is presented to the immune system. (JPG 72 kb)
41577_2003_BFnri1250_MOESM2_ESM.jpg
Cartoon 2 | The perils of protein biogenesis. All proteins are made by the ribosome using messenger RNA as a template. Nascent proteins are frequently stabilized by heat-shock proteins (HSPs), which probably facilitate correct folding and prevent aggregation. Despite this, a marked fraction of translation products is defective, resulting in incorrect (mistranslated or prematurely stopped), misfolded or misassembled proteins. These defective ribosomal products (DRiPs) are shunted to the proteasome for degradation, coupling protein production to MHC class I antigen presentation and enable a rapid T-cell response to new viral proteins. (JPG 84 kb)
41577_2003_BFnri1250_MOESM3_ESM.jpg
Cartoon 3 | Complexities of MHC class I antigen presentation. Both defective ribosomal products (DRiPs) and mature proteins (retirees) are degraded by proteasomes, usually after polyubiquitylation. The proteasome digests proteins into peptides of various lengths. Many peptides are too small for presentation by MHC class I molecules and are recycled into amino acids that can be used for new proteins. Another fraction is appropriate or too long for MHC class I molecules. These, too, are substrates for various cytosolic peptidases that will degrade most to amino acids. Only a few (trimmed) peptides diffuse into the transporter for antigen processing (TAP). TAP translocates peptides into the lumen of the endoplasmic reticulum (ER), where they can associate with MHC class I molecules before or after trimming by ER aminopeptidases (ERAP). Peptides that fail to bind to MHC class I molecules are removed by the translocon SEC61 and enter the cytoplasm, where they will again be targets for the cytosolic peptidases. (JPG 137 kb)
Related links
Related links
DATABASES
LocusLink
Further information
Glossary
- SIGNAL PEPTIDES
-
Targeting sequences in proteins that are required to send them to their subsequent destination. This could be the mitochondrion, nucleus, peroxisome or ER, endoplasmic reticulum, depending on amino-acid sequence and positioning in the protein. Signal sequences for ER targeting enter the ER lumen, are cleaved off, and can end up as an MHC class-I-binding peptide.
- ERAP1
-
This endoplasmic-reticulum-resident aminopeptidase trims peptides to the size that is suitable for binding to MHC class I molecules. As both the proteasome and transporter for antigen processing handle peptides that are longer than those that bind to MHC class I molecules, either cytosolic peptidases and/or ERAP1 are required for correct epitope generation.
- SEC61 TRANSLOCON
-
An endoplasmic reticulum (ER) complex used by the ribosome to transfer nascent proteins into the ER lumen during translation. The same complex is also used to remove ER proteins and peptides, for transfer in the ER and degradation by the proteasome and peptidases, respectively.
- CROSS-PRIMING
-
Initiation of a CD8+ T-cell response to an antigen that is not present in antigen-presenting cells (APCs). The antigen must be taken up by APCs and then re-routed to the MHC class-I-presentation pathway.
- DEFECTIVE RIBOSOMAL PRODUCTS
-
(DRiPs). DRiPs include all proteins that are degraded by the proteasome before becoming functional. This could be the result of defects in transcription, splicing, translation, assembly or folding. DRiPs link antigen generation to presentation and ensure rapid CD8+ T-cell responses to infections.
- F-BOX PROTEINS
-
The target-recognizing subunit of the SCF (SKP1–cullin–F-box) complex. About 70 different F-box proteins are encoded in the human genome, most with unknown substrate specificity. After recognition by the F-box protein, E2 ubiquitin ligase transfers the first ubiquitin tag to the target protein, thereby initiating poly-ubiquitylation and ultimately degradation by the proteasome.
- FLUORESCENCE LOSS IN PHOTOBLEACHING
-
(FLIP). FLIP is the reverse of FRAP (fluorescence recovery after photobleaching) and is a microscopy technique used to follow the dynamics of fluorescent molecules in living cells. By bleaching fluorescence at one site in a cell, the redistribution of fluorescence to other sites illustrates the dynamics of the fluorescent probes.
Rights and permissions
About this article
Cite this article
Yewdell, J., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol 3, 952–961 (2003). https://doi.org/10.1038/nri1250
Issue Date:
DOI: https://doi.org/10.1038/nri1250
This article is cited by
-
Identification of tumor antigens with immunopeptidomics
Nature Biotechnology (2022)
-
SUMO and cellular adaptive mechanisms
Experimental & Molecular Medicine (2020)
-
Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design
Nature Communications (2020)
-
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4
Genome Medicine (2019)
-
Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides
Journal for ImmunoTherapy of Cancer (2019)